HK1179522A1 - Therapeutic combination comprising dolutegravir, abacavir and lamivudine dolutegravirabacvir lamivudine - Google Patents

Therapeutic combination comprising dolutegravir, abacavir and lamivudine dolutegravirabacvir lamivudine

Info

Publication number
HK1179522A1
HK1179522A1 HK13106716.5A HK13106716A HK1179522A1 HK 1179522 A1 HK1179522 A1 HK 1179522A1 HK 13106716 A HK13106716 A HK 13106716A HK 1179522 A1 HK1179522 A1 HK 1179522A1
Authority
HK
Hong Kong
Prior art keywords
lamivudine
dolutegravirabacvir
dolutegravir
abacavir
therapeutic combination
Prior art date
Application number
HK13106716.5A
Other languages
English (en)
Chinese (zh)
Inventor
Mark Richard Underwood
Original Assignee
Viiv Healthcare Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44319704&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK1179522(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Viiv Healthcare Co filed Critical Viiv Healthcare Co
Publication of HK1179522A1 publication Critical patent/HK1179522A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/536—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
HK13106716.5A 2010-01-27 2013-06-06 Therapeutic combination comprising dolutegravir, abacavir and lamivudine dolutegravirabacvir lamivudine HK1179522A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US29858910P 2010-01-27 2010-01-27
PCT/US2011/022219 WO2011094150A1 (en) 2010-01-27 2011-01-24 Antiviral therapy

Publications (1)

Publication Number Publication Date
HK1179522A1 true HK1179522A1 (en) 2013-10-04

Family

ID=44319704

Family Applications (3)

Application Number Title Priority Date Filing Date
HK18109751.0A HK1250335A1 (zh) 2010-01-27 2013-06-06 抗病毒治療
HK13106716.5A HK1179522A1 (en) 2010-01-27 2013-06-06 Therapeutic combination comprising dolutegravir, abacavir and lamivudine dolutegravirabacvir lamivudine
HK15110408.8A HK1209629A1 (en) 2010-01-27 2013-06-06 Antiviral therapy

Family Applications Before (1)

Application Number Title Priority Date Filing Date
HK18109751.0A HK1250335A1 (zh) 2010-01-27 2013-06-06 抗病毒治療

Family Applications After (1)

Application Number Title Priority Date Filing Date
HK15110408.8A HK1209629A1 (en) 2010-01-27 2013-06-06 Antiviral therapy

Country Status (45)

Country Link
US (12) US20120295898A1 (ar)
EP (6) EP2932970B1 (ar)
JP (8) JP2013518107A (ar)
KR (4) KR20170078868A (ar)
CN (2) CN105311033B (ar)
AP (1) AP3551A (ar)
AU (1) AU2011209788C1 (ar)
BR (1) BR112012018670A2 (ar)
CA (4) CA2967453C (ar)
CL (1) CL2012002080A1 (ar)
CO (1) CO6602152A2 (ar)
CR (1) CR20120423A (ar)
CY (4) CY1116509T1 (ar)
DK (4) DK3494972T3 (ar)
DO (2) DOP2012000205A (ar)
EA (4) EA037601B1 (ar)
EC (1) ECSP12012106A (ar)
ES (4) ES2670811T3 (ar)
FI (2) FI3494972T3 (ar)
FR (2) FR18C1043I2 (ar)
HK (3) HK1250335A1 (ar)
HR (4) HRP20240168T1 (ar)
HU (6) HUE065569T2 (ar)
IL (5) IL221007A (ar)
LT (4) LT3494972T (ar)
LU (1) LUC00090I2 (ar)
MA (1) MA34002B1 (ar)
ME (2) ME03058B (ar)
MX (4) MX367938B (ar)
MY (2) MY188334A (ar)
NO (2) NO2932970T3 (ar)
NZ (4) NZ627824A (ar)
PE (2) PE20160180A1 (ar)
PH (2) PH12016500195A1 (ar)
PL (4) PL2531027T3 (ar)
PT (4) PT3127542T (ar)
RS (4) RS54123B1 (ar)
SG (3) SG10201707183TA (ar)
SI (4) SI3127542T1 (ar)
SM (1) SMT201500177B (ar)
TN (1) TN2012000376A1 (ar)
TR (1) TR201807704T4 (ar)
UA (1) UA105556C2 (ar)
WO (1) WO2011094150A1 (ar)
ZA (1) ZA201205586B (ar)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS54123B1 (en) 2010-01-27 2015-12-31 Viiv Healthcare Company THERAPEUTIC COMBINATION CONTAINING DOLUTEGRAVIR, ABACAVIR AND LAMIVUDINE
CN104884063A (zh) 2012-10-23 2015-09-02 西普拉有限公司 抗逆转录病毒药物组合物
KR102406288B1 (ko) 2012-12-21 2022-06-13 길리애드 사이언시즈, 인코포레이티드 폴리시클릭-카르바모일피리돈 화합물 및 그의 제약 용도
EP2767272A1 (en) * 2013-02-18 2014-08-20 Ratiopharm GmbH Solid pharmaceutical dosage form of dolutegravir
WO2014125124A1 (en) * 2013-02-18 2014-08-21 Ratiopharm Gmbh Solid pharmaceutical dosage form of dolutegravir
ES2859102T3 (es) 2013-07-12 2021-10-01 Gilead Sciences Inc Compuestos de carbamoilpiridona policíclica y su uso para el tratamiento de infecciones por VIH
NO2865735T3 (ar) 2013-07-12 2018-07-21
MX367057B (es) 2013-09-27 2019-08-02 Merck Sharp & Dohme Derivados de quinolizina sustituidos utiles como inhibidores de integrasa del vih.
WO2015140569A1 (en) 2014-03-20 2015-09-24 Cipla Limited Pharmaceutical composition
US10300074B2 (en) 2014-06-04 2019-05-28 Sanford Burnham Prebys Medical Discovery Institute Use of inhibitor of apoptosis protein (IAP) antagonists in HIV therapy
NO2717902T3 (ar) 2014-06-20 2018-06-23
TW201613936A (en) 2014-06-20 2016-04-16 Gilead Sciences Inc Crystalline forms of(2R,5S,13aR)-8-hydroxy-7,9-dioxo-n-(2,4,6-trifluorobenzyl)-2,3,4,5,7,9,13,13a-octahydro-2,5-methanopyrido[1',2':4,5]pyrazino[2,1-b][1,3]oxazepine-10-carboxamide
TWI677489B (zh) 2014-06-20 2019-11-21 美商基利科學股份有限公司 多環型胺甲醯基吡啶酮化合物之合成
JP6603306B2 (ja) 2014-07-29 2019-11-06 レツク・フアーマシユーテイカルズ・デー・デー ドルテグラビルナトリウムの新規な水和物
TWI738321B (zh) 2014-12-23 2021-09-01 美商基利科學股份有限公司 多環胺甲醯基吡啶酮化合物及其醫藥用途
BR112017020837A2 (pt) 2015-04-02 2018-07-03 Gilead Sciences, Inc. compostos de carbamoilpiridona policíclicos e seu uso farmacêutico
EP3334419A1 (en) * 2015-08-14 2018-06-20 Sandoz AG Solid pharmaceutical composition of abacavir, lamivudine, and efavirenz
WO2017205585A1 (en) * 2016-05-27 2017-11-30 Viiv Healthcare Company Combinations and uses treatments thereof
WO2018028841A1 (en) * 2016-08-12 2018-02-15 Sandoz Ag Solid pharmaceutical composition of abacavir, lamivudine, and efavirenz
WO2018042332A1 (en) * 2016-08-31 2018-03-08 Glaxosmithkline Intellectual Property (No.2) Limited Combinations and uses and treatments thereof
US20200138845A1 (en) * 2017-07-18 2020-05-07 Viiv Healthcare Company Combination Drug Therapy
JP2020528413A (ja) * 2017-07-21 2020-09-24 ヴィーブ ヘルスケア カンパニー Ｈｉｖ感染症及びａｉｄｓを治療するためのレジメン
CN111107850A (zh) 2017-07-21 2020-05-05 Viiv保健公司 用于治疗hib感染和aids的方案
KR20200070246A (ko) * 2017-10-13 2020-06-17 비이브 헬쓰케어 컴퍼니 이중층 제약 정제 제제
EP3938047B1 (en) 2019-03-22 2022-06-22 Gilead Sciences, Inc. Bridged tricyclic carbamoylpyridone compounds and their pharmaceutical use
WO2021142150A1 (en) * 2020-01-09 2021-07-15 University Of Washington Long-acting therapeutic agent combinations and methods thereof
PE20221569A1 (es) 2020-02-24 2022-10-06 Gilead Sciences Inc Compuestos tetraciclicos para el tratamiento de infecciones por vih
HRP20231654T1 (hr) 2021-01-19 2024-03-15 Gilead Sciences, Inc. Supstituirani spojevi piridotriazina i njihove uporabe
WO2023164293A1 (en) * 2022-02-28 2023-08-31 Jericho Sciences, Llc Methods for viral infections
TWI843506B (zh) 2022-04-06 2024-05-21 美商基利科學股份有限公司 橋聯三環胺甲醯基吡啶酮化合物及其用途

Family Cites Families (78)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5047407A (en) 1989-02-08 1991-09-10 Iaf Biochem International, Inc. 2-substituted-5-substituted-1,3-oxathiolanes with antiviral properties
US7119202B1 (en) 1989-02-08 2006-10-10 Glaxo Wellcome Inc. Substituted-1,3-oxathiolanes and substituted-1,3-dioxolanes with antiviral properties
GB8815265D0 (en) 1988-06-27 1988-08-03 Wellcome Found Therapeutic nucleosides
GB9009861D0 (en) 1990-05-02 1990-06-27 Glaxo Group Ltd Chemical compounds
ZA923641B (en) 1991-05-21 1993-02-24 Iaf Biochem Int Processes for the diastereoselective synthesis of nucleosides
GB9111902D0 (en) 1991-06-03 1991-07-24 Glaxo Group Ltd Chemical compounds
GB9204015D0 (en) 1992-02-25 1992-04-08 Wellcome Found Therapeutic nucleosides
US5519021A (en) 1992-08-07 1996-05-21 Merck & Co., Inc. Benzoxazinones as inhibitors of HIV reverse transcriptase
IL106507A (en) 1992-08-07 1997-11-20 Merck & Co Inc Pharmaceutical compositions containing benzoxazinones and some novel compounds of this type
GB9402161D0 (en) 1994-02-04 1994-03-30 Wellcome Found Chloropyrimidine intermediates
IL113432A (en) 1994-04-23 2000-11-21 Glaxo Group Ltd Process for the diastereoselective synthesis of nucleoside analogues
UA49803C2 (uk) 1994-06-03 2002-10-15 Дж.Д. Сьорль Енд Ко Спосіб лікування ретровірусних інфекцій
MY115461A (en) 1995-03-30 2003-06-30 Wellcome Found Synergistic combinations of zidovudine, 1592u89 and 3tc
US5914332A (en) 1995-12-13 1999-06-22 Abbott Laboratories Retroviral protease inhibiting compounds
US5849911A (en) 1996-04-22 1998-12-15 Novartis Finance Corporation Antivirally active heterocyclic azahexane derivatives
PL330747A1 (en) * 1996-06-25 1999-05-24 Glaxo Group Ltd Vx478, zidovudin, ftc and/or 3tc containing combinations for use in treating hiv infections
US5922695A (en) 1996-07-26 1999-07-13 Gilead Sciences, Inc. Antiviral phosphonomethyoxy nucleotide analogs having increased oral bioavarilability
US5965729A (en) 1997-02-05 1999-10-12 Merck & Co., Inc. Process for the crystallization of a reverse transcriptase inhibitor using an anti-solvent
GB9709945D0 (en) 1997-05-17 1997-07-09 Glaxo Group Ltd A novel salt
US5935946A (en) 1997-07-25 1999-08-10 Gilead Sciences, Inc. Nucleotide analog composition and synthesis method
GB9717928D0 (en) 1997-08-22 1997-10-29 Glaxo Group Ltd Process for the enatioselective hydrolysis of n-derivatised lactams
GB9721780D0 (en) 1997-10-14 1997-12-10 Glaxo Group Ltd Process for the synthesis of chloropurine intermediates
US6436989B1 (en) 1997-12-24 2002-08-20 Vertex Pharmaceuticals, Incorporated Prodrugs of aspartyl protease inhibitors
US6087383A (en) 1998-01-20 2000-07-11 Bristol-Myers Squibb Company Bisulfate salt of HIV protease inhibitor
GB9805898D0 (en) 1998-03-20 1998-05-13 Glaxo Group Ltd Process for the sythesis of hiv protease inhibitors
WO1999048371A1 (en) 1998-03-27 1999-09-30 The Regents Of The University Of California Novel hiv integrase inhibitors and hiv therapy based on drug combinations including integrase inhibitors
UA72207C2 (uk) 1998-04-07 2005-02-15 Брістол- Майєрс Сквібб Фарма Компані Фармацевтична композиція ефавіренцу з добавкою дезінтегруючих агентів у вигляді швидкорозчинних капсул або таблеток та спосіб її виготовлення
GB9809213D0 (en) * 1998-04-29 1998-07-01 Glaxo Group Ltd Pharmaceutical compositions
GB9815567D0 (en) 1998-07-18 1998-09-16 Glaxo Group Ltd Antiviral compound
CA2398640C (en) 2000-01-31 2011-06-14 Cook Biotech Incorporated Stent valves and uses of same
PL217629B1 (pl) 2001-04-10 2014-08-29 Pfizer Pochodne pirazolu i kompozycje farmaceutyczne zawierające je oraz ich zastosowanie
US7638522B2 (en) * 2001-08-13 2009-12-29 Janssen Pharmaceutica N.V. Salt of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino] benzonitrile
MY169670A (en) 2003-09-03 2019-05-08 Tibotec Pharm Ltd Combinations of a pyrimidine containing nnrti with rt inhibitors
JO3429B1 (ar) * 2001-08-13 2019-10-20 Janssen Pharmaceutica Nv مشتقات برميدينات مثبطة فيروس الايدز
AR040242A1 (es) 2002-06-04 2005-03-23 Glaxo Group Ltd Composiciones farmaceuticas
US20060084627A1 (en) 2002-06-27 2006-04-20 Medivir Ab Synergistic interaction of abacavir and alovudine
SI1583542T1 (sl) * 2003-01-14 2008-12-31 Gilead Sciences Inc Sestavki in postopki za kombinacijsko antivirusnoterapijo
TW200510425A (en) 2003-08-13 2005-03-16 Japan Tobacco Inc Nitrogen-containing fused ring compound and use thereof as HIV integrase inhibitor
AU2005211733A1 (en) 2004-02-11 2005-08-25 Shionogi & Co., Ltd HIV integrase inhibitors
JP4285353B2 (ja) 2004-03-05 2009-06-24 清水建設株式会社 化学物質放散度評価方法
ES2315922T3 (es) * 2004-04-14 2009-04-01 Gilead Sciences, Inc. Analogos de fosfonato de compuestos inhibidores de la integrasa del vih.
JP4629104B2 (ja) * 2004-05-21 2011-02-09 日本たばこ産業株式会社 ４−オキソキノリン誘導体および抗ｈｉｖ剤を含む併用剤
US7176196B2 (en) 2004-05-28 2007-02-13 Bristol-Myers Squibb Company Bicyclic heterocycles as HIV integrase inhibitors
EP1930011B1 (en) 2004-08-23 2011-08-17 Teva Pharmaceutical Industries Ltd Crystalline form of ibandronate sodium
CA2577288C (en) 2004-09-02 2010-11-30 Janssen Pharmaceutica N.V. Hydrochloride of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino]benzonitrile
PT1799696E (pt) 2004-09-17 2009-02-16 Idenix Pharmaceuticals Inc Fosfoindoles como inibidores de hiv
US7250421B2 (en) 2005-01-31 2007-07-31 University Of Georgia Research Foundation, Inc. Diketo acids with nucleobase scaffolds: anti-HIV replication inhibitors targeted at HIV integrase
US20090093454A1 (en) 2005-03-04 2009-04-09 Kristjan Gudmundsson Chemical Compounds
DK1874117T3 (da) 2005-04-28 2013-09-23 Viiv Healthcare Co Polycyklisk carbamoylpyridonderivat med hiv-integrasehæmmende aktivitet
CN101212903B (zh) * 2005-04-28 2013-07-24 史密丝克莱恩比彻姆公司 具有hiv整合酶抑制活性的多环氨基甲酰基吡啶酮衍生物
US20080280849A1 (en) 2005-06-01 2008-11-13 Herve Leh Synergic Combinations Comprising a Quinoline Compound and Other Hiv Infection Therapeutic Agents
CA2635468C (en) * 2005-12-30 2016-08-09 Gilead Sciences, Inc. Methods for improving the pharmacokinetics of hiv integrase inhibitors
UA101141C2 (ru) * 2005-12-30 2013-03-11 Гилиад Сайенсиз, Инк. Способ улучшения фармакокинетики ингибиторов интегразы вич
ES2414982T7 (es) * 2006-01-20 2021-11-05 Janssen Sciences Ireland Unlimited Co Tratamiento a largo plazo de infección por VIH con TCM278
US20080039428A1 (en) 2006-06-29 2008-02-14 Panacos Pharmaceuticals, Inc. Antiretroviral combination therapy
WO2008011117A2 (en) 2006-07-21 2008-01-24 Gilead Sciences, Inc. Antiviral protease inhibitors
CA2664396A1 (en) 2006-09-29 2008-04-10 Idenix Pharmaceuticals, Inc. Enantiomerically pure phosphoindoles as hiv inhibitors
HUE029842T2 (en) 2007-02-23 2017-04-28 Gilead Sciences Inc Modulation of pharmacokinetic parameters of therapeutic agents
US20080241289A1 (en) 2007-02-23 2008-10-02 Auspex Pharmaceuticals, Inc. Preparation and utility of non-nucleoside reverse transcriptase inhibitors
US8334295B2 (en) 2007-06-29 2012-12-18 Korea Research Institute Of Chemical Technology Pyrimidine derivatives as HIV reverse transcriptase inhibitors
KR20100041798A (ko) 2007-06-29 2010-04-22 한국화학연구원 신규 ｈｉｖ 역전사효소 억제제
WO2009008989A1 (en) 2007-07-06 2009-01-15 Gilead Sciences, Inc. Modulators of pharmacokinetic properties of therapeutics
BRPI0814548A2 (pt) 2007-07-12 2015-01-06 Tibotec Pharm Ltd Forma cristalina de 4-[[4-[[4-(2-cianoetenil)-2,6-dimetilfenil]amino]-2 pirimidinil]amino]benzonitrila
WO2009058923A1 (en) 2007-10-31 2009-05-07 Smithkline Beecham Corporation Ccr5 antagonists as therapeutic agents
JP2011502998A (ja) 2007-11-01 2011-01-27 ザ ユーエイビー リサーチ ファウンデイション ウイルス感染の治療および予防
US8108055B2 (en) 2007-12-28 2012-01-31 Larry Wong Method, system and apparatus for controlling an electrical device
CN101977924A (zh) 2008-01-03 2011-02-16 Viro化学制药公司 新的c-21-酮基羽扇烷衍生物、其制备方法和应用
JP2011508748A (ja) * 2008-01-03 2011-03-17 バイロケム ファーマ インコーポレイテッド 新規のルパン誘導体
WO2009088719A1 (en) 2008-01-04 2009-07-16 Gilead Sciences, Inc. Inhibitors of cytochrome p450
CA2714049A1 (en) 2008-02-14 2009-08-20 Virochem Pharma Inc. Novel 17.beta. lupane derivatives
WO2009148600A2 (en) * 2008-06-06 2009-12-10 Concert Pharmaceuticals, Inc. Deuterated lysine-based compounds
PT2320908E (pt) * 2008-07-25 2014-03-06 Shionogi & Co Pró-fármacos de dolutegravir
KR101733625B1 (ko) * 2008-12-11 2017-05-10 시오노기세야쿠 가부시키가이샤 카르바모일피리돈 ｈｉｖ 인테그라제 억제제 및 중간체의 합성
EP3617194B1 (en) 2008-12-11 2023-11-08 VIIV Healthcare Company Processes and intermediates for carbamoylpyridone hiv integrase inhibitors
RS54123B1 (en) 2010-01-27 2015-12-31 Viiv Healthcare Company THERAPEUTIC COMBINATION CONTAINING DOLUTEGRAVIR, ABACAVIR AND LAMIVUDINE
GB201006038D0 (en) 2010-04-12 2010-05-26 Unilever Plc Improvements relating to antiviral compositions
WO2011160024A2 (en) 2010-06-17 2011-12-22 Fuzians Biomedicals, Inc. Compounds useful as antiviral agents, compositions, and methods of use
US20150094344A1 (en) 2011-04-01 2015-04-02 The Medicines Company Short-acting dihydropyridines (clevidipine) for use in reducing stroke damage

Also Published As

Publication number Publication date
US11234985B2 (en) 2022-02-01
KR20120128640A (ko) 2012-11-27
MY188334A (en) 2021-11-30
FR18C1043I2 (fr) 2019-10-11
PT3127542T (pt) 2018-11-26
RS54123B1 (en) 2015-12-31
KR20180078358A (ko) 2018-07-09
US20180098992A1 (en) 2018-04-12
US20170079982A1 (en) 2017-03-23
EP2531027A4 (en) 2013-07-03
PL3494972T3 (pl) 2024-05-27
CL2012002080A1 (es) 2012-11-30
CN102791129B (zh) 2015-09-30
MX2012008774A (es) 2012-08-17
TR201807704T4 (tr) 2018-06-21
DK2932970T3 (en) 2018-05-28
DOP2012000205A (es) 2012-10-15
EP3127542A1 (en) 2017-02-08
IL281959B (en) 2021-12-01
UA105556C2 (uk) 2014-05-26
JP2022071126A (ja) 2022-05-13
CA3003988C (en) 2020-01-07
CA3060290A1 (en) 2011-08-04
WO2011094150A1 (en) 2011-08-04
LTPA2018013I1 (lt) 2018-11-12
JP6268386B2 (ja) 2018-01-31
EP2932970A1 (en) 2015-10-21
HUS1800042I1 (hu) 2018-11-28
NZ627826A (en) 2016-01-29
KR20160111536A (ko) 2016-09-26
IL221007A0 (en) 2012-09-24
EA201690872A3 (ru) 2016-12-30
BR112012018670A2 (pt) 2018-02-06
IL245182A0 (en) 2016-06-30
HUE026849T2 (en) 2016-08-29
JP2016145204A (ja) 2016-08-12
HUE040554T2 (hu) 2019-03-28
ES2969969T3 (es) 2024-05-23
ES2543066T3 (es) 2015-08-14
DK3494972T3 (da) 2024-01-29
LT3494972T (lt) 2024-03-12
SG10201509476RA (en) 2015-12-30
EA025176B1 (ru) 2016-11-30
AU2011209788C1 (en) 2014-08-28
CY1116509T1 (el) 2017-03-15
PT2531027E (pt) 2015-09-16
PT3494972T (pt) 2024-02-12
HRP20180855T1 (hr) 2018-06-29
CY2018029I1 (el) 2019-07-10
HRP20240168T1 (hr) 2024-04-26
IL221007A (en) 2016-06-30
EP3494972B1 (en) 2023-12-13
MY202778A (en) 2024-05-21
SMT201500177B (it) 2015-09-07
US20210401850A1 (en) 2021-12-30
US20120295898A1 (en) 2012-11-22
NO2932970T3 (ar) 2018-08-18
EA032868B1 (ru) 2019-07-31
EP2531027B1 (en) 2015-05-06
EP4316599A2 (en) 2024-02-07
KR101964923B1 (ko) 2019-04-02
JP2019167371A (ja) 2019-10-03
IL267658B (en) 2021-04-29
EA202190473A2 (ru) 2021-06-30
HK1209629A1 (en) 2016-04-08
AU2011209788B2 (en) 2014-02-06
US20180200254A1 (en) 2018-07-19
HUE037812T2 (hu) 2018-09-28
RS57323B1 (sr) 2018-08-31
SG182614A1 (en) 2012-08-30
EA201892277A1 (ru) 2019-03-29
SI3127542T1 (sl) 2018-11-30
SI2932970T1 (en) 2018-07-31
RS57728B1 (sr) 2018-12-31
CA2787691A1 (en) 2011-08-04
CY1120457T1 (el) 2019-07-10
PL3127542T3 (pl) 2019-03-29
EP4316599A3 (en) 2024-04-10
EA037601B1 (ru) 2021-04-20
EP3351249A1 (en) 2018-07-25
EP2932970B1 (en) 2018-03-21
EP2531027A1 (en) 2012-12-12
JP2021091705A (ja) 2021-06-17
HK1250335A1 (zh) 2018-12-14
PT2932970T (pt) 2018-06-08
US20170119777A1 (en) 2017-05-04
SI2531027T1 (sl) 2015-08-31
NZ627824A (en) 2016-02-26
MX367937B (es) 2019-09-12
AP3551A (en) 2016-01-18
PE20160180A1 (es) 2016-05-04
LTC2932970I2 (lt) 2022-04-25
EA202190473A3 (ru) 2021-12-31
IL267658A (en) 2019-08-29
DK2531027T3 (en) 2015-07-20
FI3494972T3 (fi) 2024-03-01
KR101830715B1 (ko) 2018-04-04
US20150238496A1 (en) 2015-08-27
EA201290583A1 (ru) 2013-04-30
HUE065569T2 (hu) 2024-06-28
SG10201707183TA (en) 2017-10-30
SI3494972T1 (sl) 2024-03-29
CA3060290C (en) 2022-07-12
MX356891B (es) 2018-06-19
LT2932970T (lt) 2018-06-25
CN105311033A (zh) 2016-02-10
TN2012000376A1 (en) 2014-01-30
CN102791129A (zh) 2012-11-21
FR24C1024I1 (fr) 2024-07-26
IL257267B (en) 2019-08-29
RS65183B1 (sr) 2024-03-29
DK3127542T3 (en) 2018-11-12
JP2023085431A (ja) 2023-06-20
CR20120423A (es) 2012-11-22
AP2012006445A0 (en) 2012-08-31
MX367938B (es) 2019-09-12
PL2932970T3 (pl) 2018-08-31
PH12016500195B1 (en) 2016-12-05
PL2531027T3 (pl) 2016-01-29
US20200230147A1 (en) 2020-07-23
ME03058B (me) 2019-01-20
KR20170078868A (ko) 2017-07-07
EP3494972A1 (en) 2019-06-12
EP3127542B1 (en) 2018-08-22
US10426780B2 (en) 2019-10-01
ES2670811T3 (es) 2018-06-01
ES2688925T3 (es) 2018-11-07
NO2018036I1 (no) 2018-10-15
CA2967453A1 (en) 2011-08-04
PH12016500195A1 (en) 2016-12-05
PH12018502489A1 (en) 2020-06-15
CA3003988A1 (en) 2011-08-04
FR18C1043I1 (ar) 2018-11-30
LT3127542T (lt) 2018-11-26
US20170216284A1 (en) 2017-08-03
PE20121524A1 (es) 2012-12-03
FIC20240016I1 (fi) 2024-05-31
HRP20181531T1 (hr) 2018-11-16
JP2017008087A (ja) 2017-01-12
HUS2400017I1 (hu) 2024-06-28
CO6602152A2 (es) 2013-01-18
ME02182B (me) 2015-10-20
CA2787691C (en) 2018-07-17
CA2967453C (en) 2018-07-17
NZ601319A (en) 2014-08-29
ZA201205586B (en) 2014-01-29
IL281959A (en) 2021-05-31
CN105311033B (zh) 2019-05-07
IL245182B (en) 2018-04-30
HRP20150770T1 (hr) 2015-08-28
US20160339033A1 (en) 2016-11-24
JP2018127473A (ja) 2018-08-16
IL257267A (en) 2018-03-29
AU2011209788A1 (en) 2012-08-16
US20160199379A1 (en) 2016-07-14
US20170281636A1 (en) 2017-10-05
CY2018029I2 (el) 2019-07-10
KR101883750B1 (ko) 2018-07-31
ECSP12012106A (es) 2013-05-31
DOP2021000147A (es) 2022-01-16
NZ627827A (en) 2016-02-26
CY1121040T1 (el) 2019-12-11
EA201690872A2 (ru) 2016-08-31
MA34002B1 (fr) 2013-02-01
LUC00090I2 (ar) 2019-01-08
JP2013518107A (ja) 2013-05-20

Similar Documents

Publication Publication Date Title
HK1179522A1 (en) Therapeutic combination comprising dolutegravir, abacavir and lamivudine dolutegravirabacvir lamivudine
IL222481A0 (en) Combination therapy
EP2552323A4 (en) COMBINATION THERAPY
GB201005394D0 (en) Therapy
GB0905485D0 (en) Antiviral therapy
GB0916997D0 (en) Combination therapy
EP2629766A4 (en) COMBINATION THERAPY
GB201011138D0 (en) Vaporiser
GB0907973D0 (en) Combination therapy
GB0922098D0 (en) Therapeutic use
GB0903321D0 (en) Therapy
GB0914820D0 (en) WATerian therapy
GB0921244D0 (en) Therapy
GB0903319D0 (en) Therapy
GB0903145D0 (en) Medicaments uses and methods
GB0908952D0 (en) Antiviral therapy
GB0904261D0 (en) New therapeutic use
GB0901902D0 (en) Medicament
GB0903318D0 (en) Medicament

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20190124